Enhanced CAR T cell therapy offers new strategy for lymphoma
A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.
from Latest Science News -- ScienceDaily https://ift.tt/oKJbH7i
from Latest Science News -- ScienceDaily https://ift.tt/oKJbH7i
Comments
Post a Comment